Out-of-spec assay drove Teva to recall antibiotic from Canadian plant

By Staff reporter

- Last updated on GMT

Image: iStock/eartzen
Image: iStock/eartzen

Related tags: Management, Teva

An out-of-specification assay result resulted in Teva recalling over 50,000 bottles of the antibiotic amoxicillin made at a facility in Canada.

The recall of 53,328 bottles of Teva-Amoxicillin FOS 400mg/5ml 50ml bottles was for the USA market and was implemented on June 27 to the retail level, but classified with the US Food and Drug Administration (FDA) last week.

According to a Teva spokesman, the lot was manufactured at the Teva Canada Limited plant located in Markham, Ontario.

The issue was discovered during evaluation of stability samples by Quality Assurance,”​ he told in-Pharmatechnologist.com. “The decision was made to recall the product due to an out-of-specification assay result for a single lot discovered during this scheduled stability testing.”

He added the out-of-specification result was “due to an isolated packaging issue and is not indicative of a stability failure.”​ As such, appropriate actions and measures were implemented to prevent recurrence.

“The supply of this product has not been impacted and Teva continues to supply to the market. Teva continues to strictly follow quality practices in-line with the compliance requirements and industry standards to ensure our products are safe and of the top quality.”

This is not the first recall of the antibiotic amoxicillin Teva has initiated. In June 2013, a voluntary nationwide recall of 758,554 bottles took place due to discolouration of the product. A yellow to brown amoxicillin powder on the inner foil seal of the bottles was discovered, and the recall was expanded to include a further 109,080 bottles made at the Ontario facility.

And earlier this month​, the Israeli drug manufacturer withdrew seven lots of the injectable antibiotic amikacin sulfate due to concerns of contamination with glass particulate matter. The product was made at the firm’s Godollo, Budapest facility which was issued with an import alert​ in May.

Related topics: Markets & Regulations, QA/QC, Regulations

Related news

Show more

Related products

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Follow us


View more